Aquatic Capital Management LLC Boosts Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM

Aquatic Capital Management LLC boosted its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 73.3% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 63,946 shares of the company’s stock after purchasing an additional 27,049 shares during the quarter. Aquatic Capital Management LLC owned about 0.12% of Mirum Pharmaceuticals worth $4,688,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. CWM LLC increased its holdings in shares of Mirum Pharmaceuticals by 30.8% in the third quarter. CWM LLC now owns 683 shares of the company’s stock worth $50,000 after purchasing an additional 161 shares during the last quarter. Legal & General Group Plc grew its holdings in Mirum Pharmaceuticals by 0.4% during the 2nd quarter. Legal & General Group Plc now owns 43,010 shares of the company’s stock valued at $2,189,000 after buying an additional 176 shares in the last quarter. MCF Advisors LLC increased its stake in Mirum Pharmaceuticals by 76.4% in the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after acquiring an additional 185 shares during the last quarter. Jones Financial Companies Lllp increased its stake in Mirum Pharmaceuticals by 34.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 957 shares of the company’s stock worth $70,000 after acquiring an additional 243 shares during the last quarter. Finally, Arizona State Retirement System raised its holdings in shares of Mirum Pharmaceuticals by 2.6% during the 3rd quarter. Arizona State Retirement System now owns 10,984 shares of the company’s stock worth $805,000 after acquiring an additional 275 shares in the last quarter.

Mirum Pharmaceuticals Stock Performance

NASDAQ:MIRM opened at $92.64 on Tuesday. The firm has a market capitalization of $5.59 billion, a PE ratio of -193.00 and a beta of 0.52. The stock’s fifty day moving average is $95.73 and its 200 day moving average is $80.84. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $36.88 and a fifty-two week high of $109.28. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.55 and a current ratio of 2.67.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative return on equity of 8.53% and a negative net margin of 4.48%.The firm had revenue of $148.93 million for the quarter, compared to analysts’ expectations of $141.78 million. During the same period in the previous year, the firm earned $1.00 earnings per share. The firm’s quarterly revenue was up 49.8% compared to the same quarter last year. On average, sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Insider Transactions at Mirum Pharmaceuticals

In related news, CEO Christopher Peetz sold 9,108 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $103.30, for a total value of $940,856.40. Following the sale, the chief executive officer directly owned 160,294 shares of the company’s stock, valued at $16,558,370.20. This represents a 5.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Jolanda Howe sold 968 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $103.30, for a total transaction of $99,994.40. Following the completion of the sale, the senior vice president directly owned 4,503 shares of the company’s stock, valued at approximately $465,159.90. The trade was a 17.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 45,136 shares of company stock worth $4,352,029. 22.87% of the stock is currently owned by insiders.

Analyst Ratings Changes

MIRM has been the subject of a number of recent research reports. TD Cowen raised their target price on shares of Mirum Pharmaceuticals from $115.00 to $117.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Stifel Nicolaus increased their price objective on shares of Mirum Pharmaceuticals from $98.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Friday, December 19th. Citizens Jmp reduced their target price on shares of Mirum Pharmaceuticals from $140.00 to $132.00 and set a “market outperform” rating on the stock in a report on Thursday, February 26th. Finally, HC Wainwright upped their target price on shares of Mirum Pharmaceuticals from $102.00 to $130.00 and gave the company a “buy” rating in a research report on Monday, January 26th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Mirum Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $117.00.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.